Core Insights - The 67th American Society of Hematology Annual Meeting (ASH 2025) took place from December 6 to 9 in Orlando, showcasing advancements in hematology and attracting global experts [1][15] - Kangsheng Global Group, a leading Chinese diagnostic company specializing in hematology, presented its capabilities in precision diagnosis, companion diagnostics, and laboratory services at booth 1181 [1][15] Group 1: Event Highlights - The Kangsheng booth attracted numerous international visitors, facilitating discussions on CAR-T therapy optimization, CRISPR gene editing applications, minimal residual disease (MRD) monitoring, and standardization of molecular diagnostics in hematology [1][14] - The atmosphere at the conference was vibrant, with deep dialogues among top experts, pharmaceutical R&D leaders, and representatives from biotech companies and CROs [1][14] Group 2: Business Focus - Haixi Bio, a specialized platform under Kangsheng, showcased its comprehensive product system in fusion gene testing, targeted gene panels, and automated bioinformatics analysis, gaining significant attention from international peers [3][17] - Kangsheng established direct communication channels with several globally renowned pharmaceutical and biotech companies during the conference, aiming to build an efficient international collaboration network [5][19] Group 3: Research Contributions - Multiple research findings from Kangsheng were selected for poster presentations at ASH 2025, highlighting the company's depth in research and clinical value in precision medicine for hematological malignancies [7][21] - Research 4972 analyzed immune gene rearrangements in 79 Chinese multiple myeloma patients, revealing a strong correlation between Ig clone proportions and treatment efficacy, with a new prognostic model showing high discrimination (AUC=0.988) [21][22] - Research 1929 proposed a novel strategy to reverse CAR-T cell exhaustion in PD-L1 high large B-cell lymphoma, demonstrating enhanced proliferation and anti-tumor function through a combination of IL-7/CCL19 armored CAR-T cells and timed PD-1 blockade [22][10] - Research 5778 utilized targeted capture sequencing to identify driver mutations in 101 newly diagnosed multiple myeloma patients, constructing an accurate prognostic model that outperformed traditional staging systems [24][12] Group 4: Future Directions - Despite the conclusion of ASH 2025, the pursuit of innovation in hematology continues, with Kangsheng committed to leveraging its technological expertise and network to enhance international cooperation and align precision diagnostic technologies with clinical needs [15][28]
ASH 2025 圆满收官 | 康圣环球携前沿成果亮相奥兰多，共绘血液学新蓝图